How does Ilumya compare to other treatments?
Ilumya (tildrakizumab) is a biologic that was FDA approved for the treatment of moderate-to-severe plaque psoriasis in adults in 2018. There are now at least eleven biologics that have been approved to treat psoriasis; however, few trials compare one to another. All are more effective than placebo (a treatment that has no active ingredient). Other biologics approved to treat plaque psoriasis include:
These agents differ in the way that they work (some inhibit tumor necrosis factor [TNF], others block cytokines, such as interleukin 12 (IL-12), IL-23 or IL-17). They also differ in how frequently they need to be administered and there is some difference in cost.
According to guidelines issued by the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) in 2019 regarding the choice of biologics for plaque psoriasis:
How does Ilumya compare with other IL-23 inhibitors?
The IL-23 monoclonal antibodies are the most recent generation of psoriasis biologics.
Ilumya was the second IL-23 inhibitor approved behind Johnson and Johnson’s Tremfya (guselkumab) which was approved in 2017. There is also a combined IL-12/23 inhibitor called Stelara (ustekinumab) that was first approved for plaque psoriasis in adults in 2009, and the approval then expanded to include adolescents (2017) and then children (2020). The most recent IL-23 inhibitor to be approved is Skyrizi (risankizumab), in 2019. Important differences to note include:
Related medical questions
- How does Ilumya work to treat psoriasis?
- What are the side effects of Ilumya?
- How is Ilumya administered?
- Skyrizi vs Ilumya. What’s the difference?
- Does Ilumya treat psoriatic arthritis?
- How does Ilumya compare to other treatments?
- How long does it take Ilumya to work?
- How does Ilumya affect my immune system?
- How does Ilumya work to treat psoriasis?
- What are the side effects of Ilumya?
- How is Ilumya administered?
- Skyrizi vs Ilumya. What’s the difference?
- Does Ilumya treat psoriatic arthritis?
- How does Ilumya compare to other treatments?
- How long does it take Ilumya to work?
- How does Ilumya affect my immune system?
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions